Current investigation into the usage of established diabetes drugs in the management of PD is now under trial including sodium-glucose cotransporter 2 (SGLT2) inhibitors, glucagon-like peptide-1 receptor agonists (GLP-1RA), and dipeptidyl peptidase-4 (DPP-4) inhibitors. Here, GLP1R is linked to Parkinson disease.